Erratum: Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B (Hepatology International 10.1007/s12072-008-9081-2);Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B

Hepatology International

Volumn 2, Issue 3, 2008, Pages 361-369

  Shakado, Satoshi ^a   Watanabe, Hiroshi ^a   Tanaka, Takashi ^a   Morihara, Daisuke ^a   Nishizawa, Shinya ^a   Inomata, Shinjiro ^a   Ueda, Syuichi ^a   Matsumoto, Teruo ^a   Anan, Akira ^a   Takeyama, Yasuaki ^a   Irie, Makoto ^a   Iwata, Kaoru ^a   Sohda, Tetsuro ^a   Sakisaka, Shotaro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adefovir; Chronic hepatitis B; Lamivudine

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; JAPANESE; LIVER BIOPSY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; SALVAGE THERAPY; TREATMENT DURATION; VIRUS REACTIVATION;

EID: 51049105486     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9089-7     Document Type: Erratum

References (26)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
2. World Health Organization. Fact sheet WHO/204. Hepatitis B. Geneva, Switzerland: World Health Organization; 2003.
3. Beasley RP. Hepatitis B virus: The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
4. Hepatitis B fact sheet. Atlanta, GA: National Center for Infectious Disease, Centers for Disease Control and Prevention; 2004.
5. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
6. Manesis EK, Hadziyannis SJ. Interferon α treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001;121:101-9.
7. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
8. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
9. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12:67-71.
10. Peters M, Hann HWH, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.
11. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005;352:2673-81.
12. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial. Gut 2000;46:562-8.
13. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678-86.
14. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
15. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-12.
16. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003;37:748-55.
17. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003;52:420-4.
18. Ide T, Kumashiro R, Suzuki H, Tanikawa K, Sata M. Two-year follow-up study after treatment with lamivudine for chronic hepatitis B: Seven cases reported. Hepatol Res 2000;17:197-204.
19. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635-9.
20. Bonacini M, Kurz A, Locarnini S, Ayres A, Gibbs C. Fulminant hepatitis B due to a lamivudine-resistance mutant of HBV in a patient coinfected with HIV. Gastroenterology 2002;124:244-5.
21. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7.
22. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16.
23. Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, et al. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B. Antivir Res 2007;75:146-51.
24. Fung J, Lai CL, Yuen JC, Wong DK, Tanaka Y, Mizokami M, et al. Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. Antivir Ther 2007;12:41-6.
25. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13.
26. Manolakopoulos S, Bethanis S, Koutsounas S, Goulis J, Vlachogiannakos J, Christias E, et al. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine. Aliment Pharmacol Ther 2008;27:266-73.